Nath figured the drug might have a similar effect in people with long COVID, based in part on the PML results. Last June, Nath approached Merck to ask for supplies of Keytruda to test that hypothesis.

On March 11 2020, as COVID continued to spread rapidly around the globe, the World Health Organization (WHO) officially ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

The contract biotech company plans to invest around $50 million to buy and renovate a Baltimore facility as it shifts more ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE ... were arthralgia, COVID-19, nasopharyngitis, and fatigue. One participant on DOR/ISL discontinued due to a drug-related serious AE (immune ...

Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

On March 4, 2025, filings revealed that CEO Stephane Bancel purchased 160,314 shares of MRNA stock between $31.04 and $31.53, ...

Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant ...

Walgreens said it had entered into a settlement agreement with telemedicine provider Everly Health Solutions as part of which the pharmacy chain operator will pay the company $595 million over a ...